People
It is important to remember that this is a new virus, so researchers are constantly learning more about it every day.
Vaccine expert Rick Bright, who was abruptly dismissed from his post as director of the Biomedical Advanced Research and Development Authority (BARDA) last month, filed a whistleblower complaint against the administration over its failures to heed warnings about the COVID-19 pandemic and accused the White House of cronyism in awarding contracts.
In 1996, Udit Batra received his Ph.D. in chemical engineering from Princeton University. 24 years later, he heads a MilliporeSigma, $7.5 billion global life sciences company with a catalog of some 300,000 items used by life sciences researchers and developers throughout the world.
In an interview with National Geographic, Fauci once again sided with the evidence that indicates the virus is a species jumper and originated in the animal kingdom.
Leaders from all over the world met for a virtual summit on Monday, May 4 to pledge billions of dollars to fund development of a vaccine against COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Noticeably absent was the United States.
“We are very disappointed in the topline results in the STARS study that did not meet the study endpoints,” said Ravi Anand, Newron’s chief medical officer.
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
A vaccine for COVID-19 is unlikely to be ready in 2020, according to biopharma professionals responding to the BioSpace Workplace Survey: The Impact of COVID-19 – Spring 2020. Only 25% of respondents thought a vaccine might be possible this year.
The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients.
PRESS RELEASES